Email updates

Keep up to date with the latest news and content from BMC Research Notes and BioMed Central.

Open Access Open Badges Technical Note

A simple way to evaluate self-designed probes for tumor specific Multiplex Ligation-dependent Probe Amplification (MLPA)

Kristina Pedersen124, Emilia Wiechec12, Bo E Madsen35, Jens Overgaard2 and Lise Lotte Hansen1*

Author Affiliations

1 Institute of Human Genetics, The Bartholin building, Wilhelm Meyers Allé 4, University of Aarhus, DK-8000 Aarhus C, Denmark

2 Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark

3 Bioinformatics Research Center (BiRC), University of Aarhus, DK-8000 Aarhus C, Denmark

4 Greenbaum Cancer Center, University of Maryland, 655 West Baltimore Street; 21201 Baltimore, MD, USA

5 AgroTech, Institute for Agri Technology and Food Innovation, Udkærsvej 15, 8200 Aarhus N, Denmark

For all author emails, please log on.

BMC Research Notes 2010, 3:179  doi:10.1186/1756-0500-3-179

Published: 26 June 2010



The Multiplex Ligation-dependent Probe Amplification (MLPA) is widely used for analysis of copy number variations (CNVs) in single or multiple loci. MLPA is a versatile methodology and important tool in cancer research; it provides precise information on increased or decreased copy number at specific loci as opposed to loss of heterozygosity (LOH) studies based upon microsatellite analysis. Pre-designed MLPA kits and software are commercially available to analyze multiple exons, genes, and genomic regions. However, an increasing demand for new gene specific assays makes it necessary to self-design new MLPA probes for which the available software may not be applicable. During evaluation of new self-designed reference probes, we encountered a number of problems, especially when applying the MLPA methodology to tumor samples.


DNA samples from 48 unaffected individuals and 145 breast cancer patients were used to evaluate 11 self-designed MLPA probes and determine the cut-off values for CNV, before applying the MLPA probes to normalize the target probes in a cohort of affected individuals. To test the calculation strategy, three probes were designed to cover regions in Regulator of G-protein Signaling 8 (RGS8), which we previously have identified as being affected by allelic imbalance by LOH analysis across RGS8 in the cohort comprising 145 breast tumors. Agreement between the LOH results and the results obtained by each of the three MLPA probes in RGS8 was found for 64%, 73%, and 91%, of the analyzed samples, respectively.


Here, we present a straightforward method, based upon the normalization pattern in both unaffected and affected individuals, to evaluate self-designed reference probes and to calculate CNV for the MLPA assay with specific focus on the difficulties when analyzing tumor DNA.